ReviewFrontiers in oncology2026
Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locally advanced thymoma is characterised by significant heterogeneity and complex biological behaviour, and its optimal treatment strategy has long been controversial. The integration of minimally invasive surgical techniques and advanced radiotherapy technologies is refining the standard treatment mode towards individualised decision-making. This article reviews the latest evidence-based medical progress regarding the selection of surgical approaches and postoperative adjuvant treatment decisions for locally advanced thymoma in recent years. Regarding surgical treatment, the application boundaries of robotic and thoracoscopic minimally invasive surgery in locally advanced cases are analysed, indicating that when complete tumour resection (R0) is ensured, minimally invasive surgery can yield oncological outcomes non-inferior to those of open surgery and significantly reduce perioperative complications. Regarding radiation therapy, the evolution of indications for postoperative radiotherapy (PORT) is discussed, emphasising the critical role of risk stratification models based on WHO histological classification, resection margin status, and tumour burden in guiding radiotherapy decisions, and the potential of new technologies such as proton therapy in reducing cardiac toxicity is evaluated. This article aims to construct a dynamic individualised treatment decision-making framework by integrating multidisciplinary perspectives, providing a theoretical basis and practical guidance for clinicians to balance oncological efficacy and patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.